Out-Licensing
In association with the Viridian merger, miRagen’s business strategy transitioned to prioritizing VRDN-001 for the development of thyroid eye disease and away from its legacy programs that modulate microRNAs. The presentations and publications listed below provide data on the microRNA programs that are now available for out-licensing, spin out or sale. For further information please contact Outlicensing@viridiantherapeutics.com.
- June 12, 2009 MicroRNA control of muscle development and disease Current Opinion in Cell Biology
- June 12, 2009 AngiomiRs–key regulators of angiogenesis Current Opinion in Genetics & Development
- January 29, 2009 Searching for MiR-acles in cardiac fibrosis Circulation Research
- December 1, 2008 microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart Genes & Development
- October 23, 2008 Toward microRNA-based therapeutics for heart disease: the sense in antisense Circulation Research
- August 12, 2008 miRNA expression in the failing human heart: functional correlates Journal of Molecular and Cellular Biology
- August 12, 2008 The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis Developmental Cell
- May 23, 2008 Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis Proceedings of the National Academy of Sciences
- April 12, 2008 MicroRNAs flex their muscles Trends in Genetics
- November 7, 2007 An intragenic MEF2-dependent enhancer directs muscle-specific expression of the microRNAs 1 and 133 Proceedings of the National Academy of Sciences